Stock KH6 NEWAMSTERDAM PHARMA COMPANY N.V.
Add to a list
To use this feature you must be a member
Log inSign up

News NewAmsterdam Pharma Company N.V. Deutsche Boerse AG

Equities

KH6

NL00150012L7

Market Closed - Deutsche Boerse AG
Other stock markets
 14:29:01 28/06/2024 BST 		5-day change 1st Jan Change
17.4 EUR -0.57% Intraday chart for NewAmsterdam Pharma Company N.V. +13.73% +77.55%
06-11 NewAmsterdam Pharma Gets Another US Patent Extending IP Protection for Obicetrapib Until July 2043 MT
06-10 Transcript : NewAmsterdam Pharma Company N.V. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
NewAmsterdam Pharma Gets Another US Patent Extending IP Protection for Obicetrapib Until July 2043
MT
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
GL
Transcript : NewAmsterdam Pharma Company N.V. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
GL
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
AQ
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
GL
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
AQ
NewAmsterdam Pharma Company N.V. to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key RiskFactors for Cardiovascular Disease at Upcoming Medical Meetings
CI
Transcript : NewAmsterdam Pharma Company N.V. - Special Call
TD Cowen Starts NewAmsterdam Pharma With Buy Rating
MT
Transcript : NewAmsterdam Pharma Company N.V. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 04:35 PM
Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M
MT
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
GL
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
GL
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
AQ
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NAMS Stock
  4. KH6 Stock
  5. News NewAmsterdam Pharma Company N.V.